Single-dose rabbit Anti-thymocyte Globulin induction + Divided-dose rabbit Anti-thymocyte Globulin induction

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

End-Stage Renal Disease

Conditions

End-Stage Renal Disease, Kidney Failure

Trial Timeline

Mar 1, 2010 → Jul 1, 2014

NCT ID

NCT00906204

About Single-dose rabbit Anti-thymocyte Globulin induction + Divided-dose rabbit Anti-thymocyte Globulin induction

Single-dose rabbit Anti-thymocyte Globulin induction + Divided-dose rabbit Anti-thymocyte Globulin induction is a phase 2 stage product being developed by Sanofi for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00906204. Target conditions include End-Stage Renal Disease, Kidney Failure.

What happened to similar drugs?

8 of 9 similar drugs in End-Stage Renal Disease were approved

Approved (8) Terminated (0) Active (1)

✅donepezil HCl + donepezil HClEisaiApproved

✅Zepatier + Ribavirin + SofosbuvirMerckApproved

✅Anti-Thymocyte Globulin vs Campath-1H vs DaclizumabRocheApproved

✅RanolazineGilead SciencesApproved

✅Rabbit Anti-thymocyte Immunoglobulin + Tacrolimus + Methylprednisolone + Mycophenolate mofetil + Mycophenolate Na + prednisoneSanofiApproved

✅rabbit anti-thymocyte globulin - single dose + mycophenolate mofetil + rabbit anti-thymocyte globulin - 4 doses + sirolimus + tacrolimusSanofiApproved

✅Pioglitazone + placebo comparatorBaxterApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00906204	Phase 2	Completed	Mar 1, 2010	Jul 1, 2014	End-Stage Renal Disease

Competing Products

20 competing products in End-Stage Renal Disease

See all competitors

Product	Company	Stage	Hype Score
Conversion to Advagraf + conversion of non-immunosuppressant drugs to once daily + Conversion to once daily MPA	Astellas Pharma	Pre-clinical	30
donepezil HCl + donepezil HCl	Eisai	Approved	43
paricalcitol	AbbVie	Phase 3	40
daptomycin + daptomycin	Merck	Phase 1	29
Letermovir 480 mg [PREVYMIS]	Merck	Phase 1	36
MK-2060 + Placebo	Merck	Phase 2	35
Zepatier + Ribavirin + Sofosbuvir	Merck	Approved	43
MK-2060 + Placebo	Merck	Phase 1	29
daptomycin	Merck	Phase 1	29
MK-2060	Merck	Phase 1	29
MK-2060 + Placebo	Merck	Phase 1	29
Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab	Roche	Approved	43
Avacopan	Amgen	Phase 1	29
Ranolazine	Gilead Sciences	Approved	43
Bosutinib + Bosutinib + Bosutinib + Bosutinib	Pfizer	Phase 1	29
CP-690,550	Pfizer	Phase 1	29
Belatacept	Bristol Myers Squibb	Pre-clinical	26
Rabbit Anti-thymocyte Immunoglobulin + Tacrolimus + Methylprednisolone + Mycophenolate mofetil + Mycophenolate Na + prednisone	Sanofi	Approved	43
rabbit anti-thymocyte globulin - single dose + mycophenolate mofetil + rabbit anti-thymocyte globulin - 4 doses + sirolimus + tacrolimus	Sanofi	Approved	43
ISIS 416858 + Placebo	Bayer	Phase 2	32